Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 59,277 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Ansbert Gadicke sold 59,277 shares of the stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $0.89, for a total transaction of $52,756.53. Following the sale, the insider owned 4,924,566 shares in the company, valued at approximately $4,382,863.74. The trade was a 1.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Ansbert Gadicke also recently made the following trade(s):

• On Thursday, December 4th, Ansbert Gadicke sold 83,230 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.97, for a total value of $80,733.10.
• On Wednesday, December 3rd, Ansbert Gadicke sold 57,225 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.87, for a total value of $49,785.75.
• On Monday, December 1st, Ansbert Gadicke sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total value of $57,261.98.
• On Friday, November 28th, Ansbert Gadicke sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total value of $20,074.23.
• On Wednesday, November 26th, Ansbert Gadicke sold 60,733 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $59,518.34.
• On Tuesday, November 25th, Ansbert Gadicke sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Ansbert Gadicke sold 88,802 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $87,025.96.
• On Friday, November 21st, Ansbert Gadicke sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Ansbert Gadicke sold 41,152 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.89, for a total transaction of $36,625.28.
• On Wednesday, November 19th, Ansbert Gadicke sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.

Werewolf Therapeutics Price Performance

Shares of Werewolf Therapeutics stock traded up $0.08 during trading hours on Thursday, reaching $1.00. 587,802 shares of the company’s stock were exchanged, compared to its average volume of 504,491. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The business has a fifty day moving average of $1.42 and a two-hundred day moving average of $1.33. The company has a market capitalization of $48.36 million, a P/E ratio of -0.61 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. As a group, research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on HOWL shares. Citigroup restated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. JMP Securities dropped their target price on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Bank of America reduced their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Finally, Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 21st. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

A number of hedge funds have recently modified their holdings of HOWL. Quadrature Capital Ltd bought a new stake in Werewolf Therapeutics during the 2nd quarter worth about $28,000. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics during the second quarter worth about $48,000. Nuveen LLC acquired a new stake in Werewolf Therapeutics in the 1st quarter valued at $71,000. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics during the first quarter worth $79,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $92,000. 64.84% of the stock is owned by institutional investors and hedge funds.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.